The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades
Abstract
Objective: To determine the long‐term outcome in patients with Wegener's granulomatosis (WG) over 4 decades in an academic hospital unit specializing in rheumatology. Methods: We included 290 patients, divided them into 2 cohorts, and compared them with the historical cohort of 155 patients. Comparisons were retrospective regarding disease manifestations, therapy, mortality, and incidence of malignancies. The historical cohort (cohort 1) included 155 patients diagnosed between 1966 and 1993, cohort 2 included 123 patients diagnosed between 1994 and 1998, and cohort 3 included 167 patients diagnosed between 1999 and 2002. Results: Over time, the interval between first symptoms and diagnosis was reduced by half (from 8 months to 4 months). Organ manifestations were similar in the 3 cohorts, and more than 80% of patients still required cyclophosphamide (CYC); however, the median cumulative dose was reduced significantly (from 67 gm in cohort 1 to 36 gm in cohort 2 and to 24 gm in cohort 3). The standardized mortality ratios (SMRs) declined (from 2.1 in cohort 1 to 1.41 in cohort 2 and to 1.03 in cohort 3), with fewer deaths related to WG and/or therapy (86.4% in cohort 1, 76.9% in cohort 2, 50% in cohort 3), decreasing relapse rates (63.9% in cohort 1, 51.2% in cohort 2, 35.3% in cohort 3), and no increased rate of malignancies. Compared with young females, young males had a considerably higher SMR (8.87 [95% confidence interval 4.05–16.8]) and more frequent renal manifestations (54.4% versus 33.8%). Conclusion: Mortality of WG patients declined over the last 4 decades, probably due to improved diagnostic and therapeutic procedures and increased awareness of WG, which led to earlier diagnosis and therapy, reduction in relapse rates, and lower cumulative CYC dose with fewer deaths related to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Self-citationJayne, D. R. W., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C. O. S., Sinico, R. A., Stegeman, C. A., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010090 · Cited by 1,125
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Self-citationde Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Self-citationDe Groot, K., Rasmussen, N., Bacon, P. A., Tervaert, J. W. C., Feighery, C., Gregorini, G., Gross, W. L., Luqmani, R., & Jayne, D. R. W. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21142 · Cited by 801
Self-citationReinhold-Keller, E., Beuge, N., Latza, U., De Groot, K., Rudert, H., Nölle, B., Heller, M., & Gross, W. L. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1021::aid-anr10>3.0.co;2-j · Cited by 696
Self-citationThe American College of Rheumatology 1990 criteria for the classification of vasculitis: Summary
Fries, J. F., Hunder, G. G., Bloch, D. A., Michel, B. A., Arend, W. P., Calabrese, L. H., Fauci, A. S., Leavitt, R. Y., Lie, J. T., Lightfoot, R. W., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330812 · Cited by 589
Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis
Talar-Williams, C., Hijazi, Y. M., Walther, M. M., Linehan, W. M., Hallahan, C. W., Lubensky, I., Kerr, G. S., Hoffman, G. S., Fauci, A. S., & Sneller, M. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-5-199603010-00003 · Cited by 537
Mukhtyar, C., Flossmann, O., Hellmich, B., Bacon, P., Cid, M., Cohen-Tervaert, J. W., Gross, W. L., Guillevin, L., Jayne, D., Mahr, A., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071936 · Cited by 419
Self-citationWestman, K. W., Bygren, P. G., Olsson, H., Ranstam, J., & Wieslander, J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v95842 · Cited by 318
Mohammad, A. J., Jacobsson, L. T. H., Mahr, A. D., Sturfelt, G., & Segelmark, M. (2007) · Rheumatology · doi:10.1093/rheumatology/kem107 · Cited by 265
Metzler, C., Miehle, N., Manger, K., Iking-Konert, C., de Groot, K., Hellmich, B., Gross, W. L., Reinhold-Keller, E., & for the German Network of Rheumatic Diseases (2007) · Rheumatology · doi:10.1093/rheumatology/kem029 · Cited by 220
Self-citationSolid malignancies among patients in the Wegener's granulomatosis etanercept trial
Stone, J. H., Holbrook, J. T., Marriott, M. A., Tibbs, A. K., Sejismundo, L. P., Min, Y. ‐., Specks, U., Merkel, P. A., Spiera, R., Davis, J. C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21869 · Cited by 206
Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide
Knight, A., Askling, J., Granath, F., Sparen, P., & Ekbom, A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019125 · Cited by 204
Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosis
Knight, A., Askling, J., & Ekbom, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10444 · Cited by 199
de Groot, K., Reinhold‐Keller, E., Tatsis, E., Paulsen, J., Heller, M., Nölle, B., & Gross, W. L. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391215 · Cited by 185
Self-citationReinhold‐Keller, E., Kekow, J., Schnabel, A., Schmitt, W. H., Heller, M., Beigel, A., Duncker, G., & Gross, W. L. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370622 · Cited by 166
Self-citationDevelopment and validation of a disease extent index for Wegener's granulomatosis.
de Groot, K., Gross, W. L., Herlyn, K., & Reinhold‐Keller, E. (2001) · PubMed · Cited by 166
Self-citationPredictors of survival and organ damage in Wegener's granulomatosis
Koldingsnes, W. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.5.572 · Cited by 157
Wegener's granulomatosis associated with renal cell carcinoma
Tatsis, E., Reinhold‐Keller, E., Steindorf, K., Feller, A. C., & Gross, W. L. (1999) · Arthritis & Rheumatism · Cited by 134
Self-citationReinhold‐Keller, E., Fink, C. O. E., Herlyn, K., Gross, W. L., & de Groot, K. (2002) · Arthritis Care & Research · doi:10.1002/art.10459 · Cited by 132
Self-citationRasmussen, N., Jayne, D. R. W., Abramowicz, D., Andrássy, K., BACON, P. A., Tervaert, J.-W. C., Dadonlené, J., Feighery, C., van Es, L. A., Ferrario, F., et al. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb06161.x · Cited by 111
Self-citationTaeger, D., Sun, Y., Keil, U., & Straíf, K. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00019 · Cited by 71
Substitution of Methotrexate for Cyclophosphamide in Wegener Granulomatosis
Villa‐Forte, A., Clark, T. M., Gomes, M. P. V.-F., CAREY, J. J., Mascha, E. J., Karafa, M., Roberson, G. A., Langford, C. A., & Hoffman, G. S. (2007) · Medicine · doi:10.1097/md.0b013e3181568ec0 · Cited by 70
Longitudinale Effekte des strukturierten Patientenschulungsprogramms für Vaskulitispatienten
Herlyn, K., Gross, W. L., & Reinhold‐Keller, E. (2008) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-008-0290-9 · Cited by 28
Self-citation
Cited by
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223764 · Cited by 768
Self-citationEfficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients
Cornec, D., Gall, E. C.-L., Fervenza, F. C., & Specks, U. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.123 · Cited by 294
Moosig, F., Bremer, J. P., Hellmich, B., Holle, J. U., Holl-Ulrich, K., Laudien, M., Matthis, C., Metzler, C., Nölle, B., Richardt, G., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201531 · Cited by 279
Self-citation
Metadata
- Authors
- Holle, J. U., Gross, W. L., Latza, U., Nölle, B., Ambrosch, P., Heller, M., Fertmann, R., & Reinhold‐Keller, E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-12-28
- Volume
- 63
- Issue
- 1
- Pages
- 257-266
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1972057477
- Cited by
- 270
- References
- 27
- FWCI
- 13.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.